Intervention not reported
Adverse events－serious Mometasone/formoterol (MF/F) versus Mometasone (MF) · patients with COPD
The intervention showed no clear difference in adverse events－serious Mometasone/formoterol (MF/F) versus… (low certainty).
1 finding from 1 review
Intervention not reported
Clinical failure (proportion of participants who were not cured or substantially improved (> 70% reduction in cough severity measure) at · children with subacute cough following acute bronchiolitis
The intervention showed no clear difference in clinical failure (proportion of participants who were not cured or… (low certainty).
1 finding from 1 review
Hospital admissions due to exacerbations: number of participants · children with asthma
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · children with asthma
1 finding from 1 review
Hospital admissions due to exacerbations: number of participants · children with asthma
Anti‐leukotrienes & ICS may leads to higher participants with exacerbations requiring hospital admission compared with higher dose ICS (low certainty).
1 finding from 1 review
Patients with serious adverse health events (duration 12 to 52 weeks) · Children and adults with persistent asthma.
Intermittent 'as needed' ICS showed no clear difference in patients with serious adverse health events (duration 12 to 52 weeks) compared with daily ICS (low certainty).
1 finding from 1 review
Patients with at least 1 exacerbation requiring emergency department/acute care visit (duration 12 to 52 weeks) · Children and adults with persistent asthma.
Intermittent 'as needed' ICS showed no clear difference in patients with at least 1 exacerbation requiring emergency… compared with daily ICS (low certainty).
1 finding from 1 review
Change from baseline AM PEFR (%) (duration 44 to 52 weeks) · Children and adults with persistent asthma.
Intermittent 'as needed' ICS showed no clear difference in change from baseline AM PEFR (%) (duration 44 to 52 weeks) compared with daily ICS (moderate certainty).
1 finding from 1 review
Asthma control · Children and adults with persistent asthma.
Intermittent 'as needed' ICS showed no clear difference in proportion of asthma control days over the period (duration 44 to 52… compared with daily ICS (moderate certainty).
1 finding from 1 review
Change from baseline mean daily use of β2‐agonists (puffs/day) (duration 24 to 44 weeks) · Children and adults with persistent asthma.
Intermittent 'as needed' ICS showed no clear difference in change from baseline mean daily use of β2‐agonists (puffs/day)… compared with daily ICS (moderate certainty).
1 finding from 1 review
Change in height · Children and adults with persistent asthma.
Intermittent 'as needed' ICS probably leads to higher change in height (cm) (duration 44 to 52 weeks) compared with daily ICS (moderate certainty).
1 finding from 1 review
Leaving the study early · Children and adults with persistent asthma.
Intermittent 'as needed' ICS showed no clear difference in overall withdrawals (duration 12 to 52 weeks) compared with daily ICS (low certainty).
1 finding from 1 review
Asthma symptoms · children with chronic asthma
1 finding from 1 review
Exacerbations · children with chronic asthma
It is very uncertain whether ciclesonide changes patients with exacerbations Number of patients with exacerbations compared with budesonide (dose ratio 1:2) (very low certainty).
1 finding from 1 review
Adverse events Number of patients with adverse events · children with chronic asthma
1 finding from 1 review
Asthma symptoms · children with chronic asthma
1 finding from 1 review
Exacerbations · children with chronic asthma
It is very uncertain whether ciclesonide changes patients with exacerbations Number of patients with exacerbations compared with fluticasone (dose ratio 1:1) (very low certainty).
1 finding from 1 review
Adverse events Number of patients with adverse events · children with chronic asthma
1 finding from 1 review
Asthma symptoms · children with chronic asthma
1 finding from 1 review
Exacerbations · children with chronic asthma
It is very uncertain whether ciclesonide changes patients with exacerbations Number of patients with exacerbations compared with fluticasone (dose ratio 1:2) (very low certainty).
1 finding from 1 review